Dojolvi™ (triheptanoin) – New orphan drug approval
June 30, 2020 - Ultragenyx announced the FDA approval of Dojolvi (triheptanoin), as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
Top